This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CEL-SCI Receives Key Japanese Patent For Its Investigational Phase III Cancer Therapy Multikine

CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Japanese patent office has issued a key patent covering CEL-SCI’s investigational cancer drug, Multikine (Leukocyte Interleukin, Injection)*. The patent, Japanese patent number 5,122,279, is titled, “A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation and/or Chemotherapy and a Novel Cytokine Mixture”. Key patents on Multikine have now been issued in the largest pharmaceutical markets in the world: the United States, European Union, China and Japan.

This invention relates to a novel effect of Multikine observed during clinical trials that CEL-SCI believes indicates it has the potential to pre-sensitize cancer cells to a therapeutic treatment such as chemotherapy, radiation therapy or immunotherapy. Phase I and II clinical studies with Multikine demonstrated that Multikine induced cancerous cells to enter into the cell cycle phase, and thereby possibly increased their vulnerability to chemotherapy and radiation therapy. Further research is required and currently underway in CEL-SCI’s Phase III clinical trial in an effort to confirm the observed potential synergies of Multikine.

In CEL-SCI’s ongoing Phase III global trial, advanced primary (not yet treated) head and neck cancer subjects randomized to Multikine treatment are administered Multikine ahead of surgery, radiation and chemotherapy, in the same way as it was given during CEL-SCI’s Phase I and II trials. A recent interim review of the safety data from the Phase III trial by an Independent Data Monitoring Committee (IDMC) raised no safety concerns. The IDMC also indicated that no safety signals were found that would call into question the benefit/risk of continuing the study. CEL-SCI considers the results of the IDMC review important since the findings from this interim review were similar to those reported by investigators during CEL-SCI’s Phase I-II trials in which the potential synergistic effects of Multikine on radiotherapy and chemotherapy were observed.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs